Teva Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals

TEVA 20.49

+2.3%

Oct 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: flatsville who wrote (289)	7/26/2001 5:59:54 AM
From: Dorine Essey	of 340

12:01 Nessuah Zannex has reiterated its "Buy" rating for Teva (Nasdaq: TEVA) and raised the target price to $79. Analyst Haim Israel: Teva has one of the strongest management teams in the industry and this, coupled with a winning strategy, drives the company to outperform average growth in the sector. Teva deserves to trade at premium to its peers. . 09:10 Israeli shares on Wall Street (Wed.): Amdocs (DOX) up 11.43% to $42.01; Check Point (CHKP) up 4.22% to $39.47; Mercury (MERQ) up 2.15% to $35.68; Precise Software (PRSE) up 18.74% to $21.99; Taro (TARO) up 1.17% to $95.13; Teva (TEVA) up 5.12% to $68.79. Creo (CREO) down 5.56% to $15.80; Marvell (MRVL) down 5.91% to $23.55; Terayon (TERN) down 11.23% to $4.90.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next